MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.

Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other ...

Sensei Biotherapeutics is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor ...

The understanding of immune biology and the development of newer generations of immunotherapies have opened a new stage to ...

KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of ...

New research has uncovered a novel mechanism that may help explain why some people with cancer respond remarkably well to immunotherapy while others don't. Researchers from the Garvan Institute of ...

Nes-Ziona, Israel, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the European Molecular Biology Organization ...

Subcutaneous allergen-specific immunotherapy has long been used in allergic rhinitis and/or asthma and has been recognized to be efficacious. However, owing to the inconvenience of injection and the ...

Company’s Shares Will Continue to Trade Under Ticker CERO on the OTC Markets SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (OTC PINK: CERO) (“CERo” or the “Company”), an innovative ...